US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Zymeworks Inc. - Common Stock (NY:ZYME)

N/A UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
From Zymeworks
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
From Zymeworks Inc.
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Turns Down All Blue's Hostile Bid ↗
Zymeworks Inc's (NYSE: ZYME) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons. 
Via Benzinga
News headline image
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
From Zymeworks Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
News headline image
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
News headline image
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks to Host Second Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Announces Plan to Become a Delaware Corporation
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire
News headline image
Analyst Ratings for Zymeworks ↗
Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
News headline image
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
News headline image
Market Selloff ↗
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
News headline image
Where Zymeworks Stands With Analysts ↗
Over the past 3 months, 4 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Scheduled For May 4, 2022 ↗
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. 
Via Benzinga
News headline image
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop ↗
Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >